Immunotoxins in Cancer Therapy
Immunotoxins (ITs) have now been studied for more than 10 years. They were found to be active under in vitro conditions and were utilized with success for the ex vivo pretreatment of human bone marrow transplantations. The new challenge today is to render them efficient under in vivo conditions. ITs assembled with whole toxins such as ricin, diphtheria toxin or Pseudomonas exotoxin show considerable nonspecific cytotoxicity due to the recognition of receptors on almost every cell type by the B-chain part of the toxins and are therefore not adequate for in vivo therapy.
KeywordsHuman Serum Albumin Leucine Incorporation Photoaffinity Label Pseudomonas Exotoxin Actuarial Disease Free Survival
Unable to display preview. Download preview PDF.
- Casellas, P., Bourrié, B. J. P., Gros, P., and Jansen, F. K., 1984, Kinetics of cytotoxicity induced by immunotoxins: Enhancement by lysosomotropic amines and carboxylic ionophores, J.of Biol.Chem., 259:9359.Google Scholar
- Casellas, P., and Jansen, F. K., 1987, Enhancement of A-chain immunotoxins by pharmacological agents, in: “Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer,” C. W. Vogel, ed., Oxford University Press, New York, 97–115.Google Scholar
- Eccles, S. A., Mcintosh, D. P., Purives, H. P., Cumber, A. J., Parnell, G. D., Forrester, J. A., Styles, J. M. and Kean, C. J., 1987, An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B-chain, Cancer Immunol.Immunother, 24:37.PubMedCrossRefGoogle Scholar
- Jansen, F. K., Blythman, H. E., Carrière, D., Casellas, P., Gros, O., Laurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H., and Voisin, G.A., 1982, Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity, Immunol.Rev., 62:185.PubMedCrossRefGoogle Scholar
- Laurent, G. D., Maraninchi, D., Gluckman, E., Vernant, J. P., Derocq, J. M., Gaspard, M., Rio, B., Michalet, M., Reiffers, J., Dreyfus, F., Casellas, P., Bouloux, C., Schneider, P., Blythman, H. E., and Jansen, F. K., 1988, Donor bone-marrow treatment with Fab T101 fragment-ricin A-chain immunotoxins prevents graft versus host desease (submitted).Google Scholar